{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:12Z","timestamp":1777934592931,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae and eyelash trichomegaly are seldom described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>A 72-year-old female cancer patient presented deteriorating facial-pinnae hypertrichosis and eyelash prolongation post cetuximab infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Consecutive cetuximab administration led to exaggerating hairy skin side effects, fully alleviated when the drug was discontinued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To the best of our knowledge, this is the first reported case of an anti-EGFR-associated diffuse pinnae hypertrichosis presentation in a female patient in literature. This distinct entity can be easily diagnosed and manipulated with early drug withdrawal. An extensive review of relevant basic molecular research is provided to increase physicians\u2019 awareness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221114073","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T23:46:41Z","timestamp":1657669601000},"page":"731-737","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pinnae and facial hypertrichosis induced by cetuximab"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-9360","authenticated-orcid":false,"given":"Dimitrios","family":"Alexandris","sequence":"first","affiliation":[{"name":"Evaggelismos Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nektarios","family":"Alevizopoulos","sequence":"additional","affiliation":[{"name":"Evaggelismos Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Palamaris","sequence":"additional","affiliation":[{"name":"Medical School of University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charikleia","family":"Gakiopoulou","sequence":"additional","affiliation":[{"name":"Medical School of University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Theocharis","sequence":"additional","affiliation":[{"name":"Medical School of University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/11531920-000000000-00000"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"ERBITUX\u00ae (cetuximab) Injection for Intravenous Infusion Initial U.S. Approval: 2004. 2004. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125084s273lbl.pdf","DOI":"10.3833\/pdr.v2004i51.783"},{"key":"e_1_3_3_4_2","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell EP","year":"2007","unstructured":"Mitchell EP, Perez-Soler R, Van Cutsem E, et al. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park) 2007; 21: 4\u20139.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.6858"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_343_17"},{"key":"e_1_3_3_8_2","first-page":"1656","article-title":"Facial hypertrichosis induced by cetuximab, an anti-EGFR monoclonal antibody","volume":"142","author":"Kerob D","year":"2006","unstructured":"Kerob D, Dupuy A, Reygagne P, et al. Facial hypertrichosis induced by cetuximab, an anti-EGFR monoclonal antibody. Arch Dermatol 2006; 142: 1656\u20131657.","journal-title":"Arch Dermatol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14815"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.062"},{"key":"e_1_3_3_11_2","first-page":"01","article-title":"Inheritance of hypertrichosis pinnae Auris-a review of literature","volume":"12","author":"Baryah N","year":"2018","unstructured":"Baryah N, Krishan K, Puri S, et al. Inheritance of hypertrichosis pinnae Auris-a review of literature. J Clin Diagnostic Res 2018; 12: 01\u201306.","journal-title":"J Clin Diagnostic Res"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm2003622"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962010000600025"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.040"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212082200"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90276-3"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402862111"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00849"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.11.016"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663177"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221114073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221114073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221114073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:19Z","timestamp":1777688839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221114073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/10781552221114073"],"URL":"https:\/\/doi.org\/10.1177\/10781552221114073","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]}}}